Tokio Marine Asset Management Co. Ltd. Sells 107 Shares of Zoetis Inc. (NYSE:ZTS)

Tokio Marine Asset Management Co. Ltd. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 0.1% during the fourth quarter, Holdings Channel reports. The firm owned 103,020 shares of the company’s stock after selling 107 shares during the quarter. Zoetis makes up approximately 1.1% of Tokio Marine Asset Management Co. Ltd.’s portfolio, making the stock its 17th largest holding. Tokio Marine Asset Management Co. Ltd.’s holdings in Zoetis were worth $20,333,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC raised its holdings in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Moisand Fitzgerald Tamayo LLC raised its holdings in shares of Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after purchasing an additional 96 shares during the period. Independence Bank of Kentucky raised its holdings in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Ramirez Asset Management Inc. bought a new stake in shares of Zoetis in the 3rd quarter valued at about $35,000. Finally, First Financial Corp IN raised its holdings in shares of Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after purchasing an additional 79 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS traded up $1.33 during mid-day trading on Wednesday, hitting $150.89. 3,640,337 shares of the company’s stock were exchanged, compared to its average volume of 3,074,906. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock’s 50-day simple moving average is $173.11 and its 200-day simple moving average is $179.58. The firm has a market cap of $69.01 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the prior year, the business posted $1.15 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities research analysts expect that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.15%. Zoetis’s dividend payout ratio is 34.12%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research analyst reports. The Goldman Sachs Group increased their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays lowered their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday. Stifel Nicolaus lowered their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $218.00.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 2,209 shares of company stock worth $371,293. Corporate insiders own 0.15% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.